For research use only. Not for therapeutic Use.
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects[1].
Ublituximab has been glycoengineered to have a low-fucose-containing, fragment crystallizable (Fc) region to allow for enhanced antibody-dependent cellular cytotoxicity[1].
| Catalog Number | I042128 |
| CAS Number | 1174014-05-1 |
| Purity | ≥95% |
| Reference | [1]. Matthew Lunning, et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 Nov 21;134(21):1811-1820. |
